ALGERNON PHARMACEUTICALS INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.13 CAD | +8.33% |
|
+44.44% | +100.00% |
| Sales 2022 | - | Sales 2023 | - | Capitalization | 2.6M 3.56M |
|---|---|---|---|---|---|
| Net income 2022 | -6M -8.2M | Net income 2023 | -6M -8.2M | EV / Sales 2022 | - |
| Net cash position 2022 | 1.41M 1.93M | Net cash position 2023 | 125K 171K | EV / Sales 2023 | - |
| P/E ratio 2022 |
-1.55
x | P/E ratio 2023 |
-0.37
x | Employees | - |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 98.36% |
More Fundamentals
* Assessed data
More news
More press releases
More news
| 1 day | +8.33% | ||
| 1 week | +44.44% | ||
| Current month | +18.18% | ||
| 1 month | +44.44% | ||
| 3 months | +62.50% | ||
| 6 months | +62.50% | ||
| Current year | +100.00% |
1 week
0.10
0.14
1 month
0.090.14
Current year
0.070.17
1 year
0.050.28
3 years
0.054.75
5 years
0.0514.50
10 years
0.0527.50
| Managers | Title | Age | Since |
|---|---|---|---|
Chris Moreau
CEO | Chief Executive Officer | 59 | 18-02-28 |
James Kinley
DFI | Director of Finance/CFO | 45 | 21-11-30 |
| Chief Operating Officer | 41 | 21-02-28 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Harry Bloomfield
CHM | Chairman | 79 | 21-09-07 |
Chris Moreau
CEO | Chief Executive Officer | 59 | 18-02-28 |
Mark Williams
BRD | Director/Board Member | 52 | 21-09-21 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-26 | 0.13 | +8.33% | 46,000 |
| 24-04-25 | 0.12 | +4.35% | 18,500 |
| 24-04-24 | 0.115 | -4.17% | 48,500 |
| 24-04-23 | 0.12 | +20.00% | 36,200 |
| 24-04-22 | 0.1 | +11.11% | 2,000 |
Delayed Quote Canadian Securities Exchange, April 26, 2024 at 12:35 pm EDT
More quotes
Algernon Pharmaceuticals Inc. is a clinical-stage drug development company. The Company is focused on developing repurposed therapeutic drugs in the areas of non-alcoholic steatohepatitis (NASH), a type of liver disease, chronic kidney disease (CKD), inflammatory bowel disease (IBD), idiopathic pulmonary fibrosis (IPF) and chronic cough as well as advancing a stroke program using N, N-Dimethyltryptamine (DMT). The Company operates through two segments, which includes the development of repurposed therapeutic drugs in Canada and the facilitation of the Companyâs lead drug candidates into off-label phase II clinical trials (humans) in Australia. The Company's pipeline includes NP-251 (Repirinast) and AP-188 (DMT). The Company, through its subsidiary, Algernon NeuroScience Inc., is developing AP-188 (DMT) as a potential treatment for stroke and traumatic brain injury (TBI) recovery. Its NP-251 is being developed as a potential treatment for kidney inflammation and fibrosis.
Calendar
Quarterly revenue - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| +100.00% | 2.05M | |
| -2.31% | 103B | |
| +0.56% | 95.28B | |
| +1.69% | 22.15B | |
| -17.37% | 21.02B | |
| -9.30% | 18.15B | |
| -41.01% | 16.74B | |
| -14.85% | 16.05B | |
| +3.21% | 13.68B | |
| +33.54% | 12.17B |
- Stock Market
- Equities
- AGN Stock
